SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| McAlevey Michael R | EVP & Chief Legal & Admin Off. | 2026-08-26 | J | 7769 | $3.3M |
| Marks Mike A | EVP and CFO | 2026-05-07 | Gift | 3336 | $0 |
| Marks Mike A | EVP and CFO | 2026-05-07 | Gift | 3336 | $0 |
| CHIDSEY JOHN | Director | 2026-04-28 | Grant/award | 809 | $0 |
| DEPARLE NANCY ANN | Director | 2026-04-28 | Grant/award | 509 | $0 |
| FRIST THOMAS F III | Director, 10% Owner | 2026-04-28 | Grant/award | 1041 | $0 |
| Frist William R | Director, 10% Owner | 2026-04-28 | Grant/award | 809 | $0 |
| Johnston Hugh F | Director | 2026-04-28 | Grant/award | 809 | $0 |
| MICHELSON MICHAEL W | Director | 2026-04-28 | Grant/award | 925 | $0 |
| Riley Wayne Joseph | Director | 2026-04-28 | Grant/award | 509 | $0 |
| Smith Andrea B | Director | 2026-04-28 | Grant/award | 509 | $0 |
| McAlevey Michael R | EVP & Chief Legal & Admin Off. | 2026-02-18 | Open-market sell | 1694 | $904K |
| McAlevey Michael R | EVP & Chief Legal & Admin Off. | 2026-02-13 | Option exercise | 5000 | $1.2M |
| McAlevey Michael R | EVP & Chief Legal & Admin Off. | 2026-02-13 | Tax withholding | 3306 | $1.8M |
| Berres Jennifer | SVP & Chief Human Res. Officer | 2026-02-11 | Open-market sell | 4010 | $2.0M |
| Berres Jennifer | SVP & Chief Human Res. Officer | 2026-02-11 | Open-market sell | 4010 | $2.1M |
| Wyatt Christopher F. | SVP & Controller | 2026-02-11 | Open-market sell | 4000 | $2.0M |
| Berres Jennifer | SVP & Chief Human Res. Officer | 2026-02-10 | Grant/award | 7116 | $0 |
| Berres Jennifer | SVP & Chief Human Res. Officer | 2026-02-10 | Tax withholding | 2515 | $1.3M |
| Cuffe Michael S. | EVP and Chief Clinical Officer | 2026-02-10 | Grant/award | 9628 | $0 |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Debt load grew $3.5B to $46.5B while the credit facility shifted from secured to unsecured, weakening creditor protections at a moment when new tariff and EHR implementation risks are simultaneously pressuring the cost structure. The combination of higher leverage, reduced covenant flexibility, unmitigable tariff exposure on medical supplies, and a large-scale EHR rollout represents a meaningful, multi-front deterioration. No offsetting risk reductions are present.
2 company-specific · 1 common-mode
Total indebtedness increased $3.5B (8%) to $46.5B. Credit facility structure shifted from secured to unsecured, reducing collateral protections and covenant flexibility.
Risks related to our indebtedness: We have significant indebtedness and may incur further indebtedness in the future. Our indebtedness could adversely affect our ability to raise additional capital…
New disclosure of EHR platform implementation risk with substantial resource requirements and potential operational disruptions. Added explicit operational resiliency language and financial resiliency initiatives tied to policy reforms.
Risks related to technology, data privacy and cybersecurity: Cybersecurity incidents or other forms of data breaches could result in the compromise of our facilities, confidential data or critical…
New disclosure of tariff risks materially escalating operating costs for medical supplies. Company acknowledges inability to fully mitigate future tariff impacts.
Risks related to macroeconomic conditions: Our overall business results may suffer during periods of significant inflation, general economic weakness or recessions or as a result of changing…
HCA Healthcare increased the size of its commercial paper program from $4.0 billion to $8.0 billion outstanding at any time, representing a material expansion of the issuer's direct financial obligations and borrowing capacity.
View raw filing on EDGAR →HCA Healthcare issued a press release on July 24, 2026 announcing its second quarter 2026 financial results, including revenues of $20.230 billion, net income of $1.699 billion, and diluted EPS of $7.62, along with updated full-year 2026 guidance.
View raw filing on EDGAR →HCA Healthcare's Board of Directors declared a quarterly cash dividend of $0.78 per share, payable September 30, 2026 to stockholders of record as of September 16, 2026.
View raw filing on EDGAR →HCA Healthcare issued a press release on July 14, 2026 announcing preliminary financial results for Q2 2026, including revenues of $20.230 billion, net income of $1.699 billion ($7.62 per diluted share), and Adjusted EBITDA of $4.027 billion, along with revised 2026 full-year guidance.
View raw filing on EDGAR →Dr. Michael Cuffe, Executive Vice President and Chief Clinical Officer, is stepping down effective August 31, 2026, with a transitional role through February 2027. This is a departure of a named executive officer from a senior leadership position. While severance benefits are mentioned, the principal disclosed action is the departure itself, making this an exec_departure event rather than exec_compensation.
View raw filing on EDGAR →